The future of effective aerosol therapies lies in the optimization of drug-to-device and device-to-drug. PARI Pharma has taken the next step and combined formulation development, next generation aerosol platforms, and aerosol characterization under one roof.

We are currently working with both the eFlow Technology (lower respiratory) and Vibrent Technology (upper respiratory) Advanced Aerosol Delivery platforms.

This multifunctional development program is the key to creating targeted therapies with high deposition amounts, low side-effect profiles, improved patient compliance…and better controlled, healthier patients.

After 100 years, we know aerosol science and aerosol delivery.

Tuesday, 02. October 2018

PARI Pharma’s eFlow® Technology device, LAMIRA™, approved as the only nebulizer system to deliver Insmed’s ARIKAYCE® (amikacin liposome inhalation suspension).

ARIKAYCE is the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients...
Thursday, 30. March 2017

PARI Pharma development featuring eFlow Technology for Bronchiolitis Obliterans Syndrome (BOS) is licensed to Breath Therapeutics.

PARI Pharma has licensed its first-in-class inhalation development program for Bronchiolitis Obliterans Syndrome (BOS) to Breath Therapeutics GmbH...
Wednesday, 02. November 2016

Sunovion Announces FDA Filing Acceptance of New Drug Application for Sun-101/eFlow® for the Treatment of Patients with Chronic Obstuctive Pulmonary Disease (COPD)

- Sun-101/eflow® (glycopyrrolate) NDA is currently under review; if approved, it would represent the first available nebulized long-acting muscarinic...
Sunovion Submits New Drug Application
Monday, 01. August 2016

Sunovion Submits New Drug Application for SUN-101/eFlow® to the FDA

For the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)
Monday, 01. August 2016

Sunovion Announces Results of Phase 3 Long-Term Safety Study

Showing SUN-101/eFlow®(glycopyrrolate) Was Well-Tolerated in People with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD)